#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

## CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 10, 2007

USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter)

Commission File No. 0-21116

Utah (State or other jurisdiction of incorporation) 87-0500306 (IRS Employer Identification Number)

3838 West Parkway Boulevard Salt Lake City, Utah 84120 (Address of principal executive offices, Zip Code)

Registrant's telephone number, including area code: (801) 954-7100

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- [] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- [] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 8.01 Other Events

On April 10, 2007, USANA Health Sciences, Inc. issued a press release announcing that its board of directors authorized an additional \$40 million for share repurchases of its common stock. The release also announced that share repurchases will be made from time-to-time, in the open market, through block trades or otherwise , and will be based on market conditions, the level of cash balances, general business opportunities, and other factors. A copy of the press release is furnished herewith as Exhibit 99 to this Current Report on Form 8-K and is incorporated herein by reference. The Company will also post this document on its corporate website, www.usanahealthsciences.com, under the "investors" link.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

## 10, 2007 (furnished herewith).

# 2

# SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

USANA HEALTH SCIENCES, INC.

By: /s/ Gilbert A. Fuller Gilbert A. Fuller, Chief Financial Officer

Date: April 10, 2007

3

### Exhibit 99

## USANA Adds Additional \$40 Million to Authorized Share Repurchase Program

SALT LAKE CITY--(BUSINESS WIRE)--April 10, 2007--USANA Health Sciences, Inc. (NASDAQ: USNA) ("USANA" or "the Company") today announced that its board of directors has authorized an additional \$40 million for share repurchases of its outstanding common stock.

Repurchases may be made from time to time, in the open market, through block trades or otherwise. The number of shares to be purchased and the timing of purchases will be based on market conditions, the level of cash balances, general business opportunities, and other factors.

"The Board has authorized additional funding for our stock repurchase program, which illustrates our confidence in our future growth potential," said Dave Wentz, president of USANA. "We will continue to explore opportunities to build long-term value for all of our stakeholders."

Today's \$40 million authorization will be in addition to the approximately \$25 million currently available. During 2006, the Company repurchased about one million shares for a total investment of nearly \$41 million.

### About USANA

USANA develops and manufactures high quality nutritional and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico, the Netherlands, and the United Kingdom. More information on USANA can be found at http://www.usanahealthsciences.com.

### Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including reliance upon our network of independent Associates, the governmental regulation of our products, manufacturing and marketing risks, and uncertainties associated with our planned international expansion. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

CONTACT: USANA Health Sciences, Inc.

Riley Timmer, 801-954-7100 (Investor Relations) investor.relations@us.usana.com or Edelman Joe Poulos, 312-240-2719 (Media)